DrugPatentWatch Database Preview
Drugs in Development Information for Staurosporine
» See Plans and Pricing
What is the development status for investigational drug Staurosporine?
Staurosporine is an investigational drug.
There have been 29 clinical trials for Staurosporine.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Memorial Sloan Kettering Cancer Center.
There is one US patent protecting this investigational drug and fourteen international patents.
Summary for Staurosporine
| US Patents | 1,143 |
| International Patents | 14,824 |
| US Patent Applications | 2,407 |
| WIPO Patent Applications | 2,233 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2017-12-01) |
| Vendors | 38 |
Recent Clinical Trials for Staurosporine
| Title | Sponsor | Phase |
|---|---|---|
| Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | National Cancer Institute (NCI) | Phase 2/Phase 3 |
| Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | National Cancer Institute (NCI) | Phase 2 |
| Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | Stanford University | Phase 2 |
Clinical Trial Summary for Staurosporine
Top disease conditions for Staurosporine
Top clinical trial sponsors for Staurosporine
US Patents for Staurosporine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Staurosporine | Start Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | Start Trial |
| Staurosporine | Start Trial | Compositions and methods for inhibiting intimal hyperplasia | Start Trial | |
| Staurosporine | Start Trial | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III | Frequency Therapeutics, Inc. (Woburn, MA) | Start Trial |
| Staurosporine | Start Trial | Efficient transport into white blood cells | Xigen Inflammation Ltd. (Limassol, CY) | Start Trial |
| Staurosporine | Start Trial | Organic compositions to treat beta-catenin-related diseases | Arrowhead Pharmaceuticals, Inc. (Pasadena, CA) | Start Trial |
| Staurosporine | Start Trial | SC-.beta. cells and compositions and methods for generating the same | President and Fellows of Harvard College (Boston, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Staurosporine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Staurosporine | Canada | CA2922341 | 2033-08-28 | Start Trial |
| Staurosporine | European Patent Office | EP3038618 | 2033-08-28 | Start Trial |
| Staurosporine | World Intellectual Property Organization (WIPO) | WO2015031608 | 2033-08-28 | Start Trial |
| Staurosporine | Australia | AU2009331921 | 2028-12-22 | Start Trial |
| Staurosporine | Australia | AU2009331922 | 2028-12-22 | Start Trial |
| Staurosporine | Canada | CA2738951 | 2028-12-22 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
